Research field (1):
Tumor diagnostics and therapeutics
Research keywords (2):
chemotherapy
, clinical oncology
Research theme for competitive and other funds (10):
2024 - 2027 DNAメチル化状態に基づいた頭頸部癌薬物療法のバイオマーカー開発
2024 - 2025 抗がん活性と抗菌活性を保有する新規ナノ粒子製剤の開発
2024 - 2025 抗腫瘍効果の増強を目的とした抗がん薬と抗菌薬のナノ粒子配合薬の開発
2017 - 2020 甲状腺未分化癌に対する新規治療法および治療薬の開発
2018 - 2019 HDAC/PI3K二重阻害活性を有する新規デプシペプチド類縁体の開発
2015 - 2017 悪性末梢神経鞘腫に対する新規治療薬の開発
2014 - 2017 HDAC/PI3K二重阻害活性を有する新規デプシペプチド類縁体の開発
2012 - 2015 A search and optimization of the novel cancer molecules target drugs with PI3K/HDAC dual inhibition
2013 - 2015 新規HDAC/PI3K dual inhibitorの開発
2013 - 2014 HADC/PI3K 2重阻害剤の開発
Show all
Papers (54):
Keita Tanita, Yoshitaka Koseki, Sanjay Kumar, Farsai Taemaitree, Asuka Mizutani, Hirotaka Nakatsuji, Ryuju Suzuki, Anh Thi Ngoc Dao, Fumiyoshi Fujishima, Hiroshi Tada, et al. Carrier-free nano-prodrugs for minimally invasive cancer therapy. Nanoscale. 2024. 16. 32. 15256-15264
Sakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, Yuya Yoshida, Keiju Sasaki, Yoshifumi Kawamura, Yuki Kasahara, Kota Ouchi, Hiroo Imai, Ken Saijo, et al. FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. Anticancer research. 2023. 43. 12. 5699-5704
Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Keigo Komine, Tomoyuki Iwasaki, Noriko Takenaga, Yuki Kasahara, Kota Ouchi, Hidekazu Shirota, et al. Comparison of efficacy and safety between carboplatin-etoposide and cisplatin-etoposide combination therapy in patients with advanced neuroendocrine carcinoma, retrospective study. Oncology. 2023
Reio Ueta, Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Keigo Komine, Kota Ouchi, Yuki Kasahara, Sakura Taniguchi, Yuya Yoshida, et al. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma. Oncology. 2023. 1-8
Ken Saijo, Hiroo Imai, Kota Ouchi, Keiju Sasaki, Yuya Yoshida, Yoshifumi Kawamura, Sakura Taniguchi, Yuki Kasahara, Keigo Komine, Hidekazu Shirota, et al. Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens. Frontiers in oncology. 2023. 13. 1230731-1230731
小峰啓吾, 高橋雅信, 高橋雅信, 岩崎智行, 岩崎智行, 大内康太, 吉田裕也, 吉田裕也, 沼倉龍之助, 沼倉龍之助, et al. Efficacy and safety of DOAC for treatments of VTE in patients undergoing cancer drug treatment. 日本臨床腫瘍学会学術集会(CD-ROM). 2023. 20th